Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü½Å¼º È«¹Ý¼º ·çǪ½º ȯÀÚ¿¡¼­ÀÇ ¾Ç¼ºÀÓÆÄÁ¾ Ä¡Çè·Ê

MALIGNANT IVMPHOMA IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT

¼Ò¼Ó »ó¼¼Á¤º¸
¿ì¼ø¼·/Soon Seop Woo °­Çмö/ÀÌ¿µ¼ö/½É±¤¼·/À¯±¤Èñ/Hag Soo Kang/Young Soo Lee/Kwang Sup Shim/Kwang Hee Yoo

Abstract

¼­·Ð
Àü½Å¼º È«¹Ý¼º ·çǪ½º´Â ±× ¿øÀÎÀÌ Á¤È®È÷ ¾Ë·ÁÁöÁö ¾ÊÀº ½ÉÇÑ Àü½ÅÇǺÎÀå¾Ö·Î ¾È¸éºÎ¿¡
³ªºñ¸ð¾çÀ¸·Î ºÐÆ÷ÇÏ´Â È«¹Ý¼º ¹ÝÁ¡À» ³ªÅ¸³»°í ÀÚ°¡¸é¿ª¼ºÁúȯÀ¸·Î¼­ ¸é¿ªÇÐÀûÀ¸·Î´Â Ç×ÇÙ
Ç×ü°¡ ÀÖ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù.
Àü½Å¼º È«¹Ý¼º ·çǪ½º, SjogrenÁõÈıº, ·ù¸¶Ä¡½º °üÀý¿° µî°ú °°Àº ÀÚ°¡¸é¿ª¼ºÁúȯ¿¡¼­´Â
ÀÓÆı¸°¡ Áõ½ÄÇÏ´Â Á¾¾ç, Áï ¹éÇ÷º´À̳ª ¾Ç¼ºÀÓÆÄÁ¾ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, °¢Á¾ ÀÓÆÄÀý ¹× ´Ù
¾çÇÑ Àå±â¿¡ ¹ß»ýµÈ °ÍÀÌ ¸¹ÀÌ º¸°íµÇ¾î ¿Ô´Ù.
Àü½Å¼º È«¹Ý¼º ·çǪ½º¿¡¼­ ¾Ç¼ºÀÓÆÄÁ¾ÀÌ ³ªÅ¸³ª´Â ÀÌÀ¯¿¡ ´ëÇؼ­´Â ¾ÆÁ÷ Á¤È®È÷ ¹àÇôÁø
°ÍÀº ¾øÀ¸³ª ¸î °¡Áö °¡¼³ ¹× ¿¬±¸°¡ ÀÖ¾î ¿Ô´Ù. ±× °¡¿îµ¥ ÇϳªÀÎ ¹ÙÀÌ·¯½º¼º ¿øÀηÐÀ¸·Î
ÀÌ °¡¼³¿¡¼­´Â ¹ÙÀÌ·¯½º°¡ Àü½Å¼º È«¹Ý¼º ·çǪ½º ȯÀÚ¿Í °°ÀÌ ¸é¿ª¹ÝÀÀÀÌ ÀúÇϵǾî Àִ ȯ
ÀÚ¿¡°Ô Á¾¾çÀ» ¹ß»ý½ÃÅ°´Â È°¼ºÃ¼·Î ÀÛ¿ëÇÏ¿© ¾Ç¼ºÀÓÆÄÁ¾ÀÌ º¸´Ù ³ôÀº ºóµµ·Î ¹ßÇöµÉ ¼ö ÀÖ
µµ·Ï ÇÑ´Ù´Â °ÍÀÌ´Ù.
¶Ç ´Ù¸¥ À̷п¡¼­´Â Àü½Å¼º È«¹Ý¼º ·çǪ½º¿¡ ±âÀÎÇÑ ¸é¿ª±âÀüÀÇ °áÇÔ°ú Àå±â°£ÀÇ Ä¡·á¾à
¹°ÀÌ ¾Ç¼ºÀÓÆÄÁ¾ÀÇ ¿øÀÎÀ̶ó°í ÇÑ´Ù. ¸é¿ª¾ïÁ¦¾à¹°Àº ¼¼Æ÷¼º ¸é¿ªÃ¼°èÀÇ Áö¿¬°ú¹Î¹ÝÀÀÀ» ¾à
È­½ÃÅ°°í ¾Ç¼ºÁ¾¾ç¼¼Æ÷ÀÇ ÀÎ½Ä ¹× °ÅºÎ¹ÝÀÀÀÌ ¾àÈ­µÇ¾î ¾Ç¼ºÁ¾¾ç¼¼Æ÷°¡ ¹æÇØ ¾øÀÌ °è¼Ó ¼º
Àå, ºÐ¿­ ÇÒ ¼ö ÀÖ°Ô ÇÑ´Ù. ¼¼Æ÷¼º ¸é¿ª±âÀüÀÇ ÀÌ»óÀº °è¼ÓÀûÀ¸·Î Á¾¾çÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ¹Ù
ÀÌ·¯½ºÀÇ ¼ºÀåÀ» °¡´ÉÇÏ°Ô ÇÏ°í ±× °á°ú Á¾¾çÁ¶Á÷ÀÌ »ýÁ¸ÇÒ ¼ö ÀÖ°Ô µÈ´Ù.
ÀúÀÚ µîÀº 5³â°£ Àü½Å¼º È«¹Ý¼º ·çǪ½º·Î ½ºÅ×·ÎÀÌµå ¹× ¸é¿ª¾ïÁ¦Á¦ µîÀ» Åõ¿© ¹ÞÀ¸¸ç Ä¡
·á¹Þ´ø ȯÀÚ°¡ »ó¾ÇÁÂÃøÀü¹æºÎ¿¡ À¶±âµÈ Á¾¹°À» ÁÖ¼Ò·Î º»°ú¿¡ ³»¿ø½Ã Á¶Á÷°Ë»ç°á°ú ¾Ç¼ºÀÓ
ÆÄÁ¾À¸·Î Áø´ÜµÇ¾î ³»°ú·Î Àü°úÈÄ Ç×¾ÏÁ¦Ä¡·á¸¦ ½ÃÇàÇÑ Áõ·Ê¸¦ Ä¡ÇèÇÏ¿´´Ù. ÀÌ¿¡ ¹®Çå°íÂû
°ú ÇÔ²² º¸°íÇÏ´Â ¹ÙÀÌ´Ù.
#ÃÊ·Ï#
Systemic lupus erythematosus is a severe cutaneous-systemic disorder of unknown
etiology. It is represented with erythematous patches on the face in 1 so-called butterfly
distribution, and characteristically classified as an autoimmune disease with antinuclear
antibodies.
The autoimmune diseases such as systemic lupus erythematosus, Sjogren syndrome,
rheumatoid arthritis have been associated with lymphoid malignancy-leukemia, malignant
lymphoma-which could involve various organs(spleen, liver, brain, mediastinal lymph
node, supraclavicular lymph nod, inguinal lymph node, cervical lymph node etc.).
Many authors have studied about the association of systemic lupus erythematosus and
malignant lymphoma, but exact etiology is still unknown. A common viral etiology for
systemic lupus erythematosus has been suggested since virus-like particles have been
found in the glomerular endothelium of patients with systemic lupus erythematosus.
These oncogenic viruses may be responsible for the higher frequency of malignant
lymphoma in patients with systemic lupus erythematosus.
In the other theory, the causes of malignant lymphoma are the defect of immune
system due to systemic lupus erythematosus and the long-term use of therapeutics for
treatment of systemic lupus erythematosus. When the cellular immune system(delayed
hypersensitivity) is impaired by immunosuppressive drugs, it is likely that the body is
no longer able to recognize and reject malignant cells as they arise; they continue to
grow and divide unhindered. The impairment of the cellular immuno system may allow
growth of oncogenic virus or the survival of neoplatic tissue.
47-year old female patient treated systemic lupus erythematosus with steroid and
immunosuppressive drugs for 5 years visited to our hospital due to elevated mass on
left upper anterior maxilla area. By performing biopsy, we diagnosed this lesion as
malignant lymphoma and referred to oncologist for chemotherapy. So we report a case
of malignant lymphoma due to systemic lupus erythematosus with review of literatures.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed